OncoMatch/Clinical Trials/NCT07132515
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Is NCT07132515 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Enoxaparin, warfarrin, or apixaban for cirrhosis.
Treatment: Enoxaparin, warfarrin, or apixaban — We will give an anticoagulant against portal vein thrombosis, and watch for the results.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Demographics
Lab requirements
Blood counts
Platelets <10000 [excluded]
Kidney function
Createnine >1.9 [excluded]
Liver function
Child A & B
Platelets<10000, Createnine >1.9
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07132515 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages